Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

Fig. 1

Study flow. We screened 80 patients and two patients were excluded due to withdrew informed consent before treatment. Hence the intention-to-treat population consisted of 78 patients, in which the efficacy and safety analyses were performed. As of December 2020, fifty-nine patients discontinued the study treatment for disease progression and intolerable adverse effect. The remaining 19 patients continued to receive pyrotinib

Back to article page